 WEST LAFAYETTE, Ind., Oct. 04, 2021 GLOBE NEWSWIRE -- Inotiv, Inc. NASDAQ:NOTV the Company, We, Our or Inotiv, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the acquisition of Plato BioPharma, Inc. PBI, a Colorado-based, in vivo pharmacology research and drug discovery company specializing in cardiovascular, renal, pulmonary and hepatic therapeutic areas. Transaction consideration totaled 15.0 million, consisting of: 10.0 million in cash; 57,587 Inotiv common shares having a value of 2.0 million based on the weighted average closing price of Company shares as reported by NASDAQ for the twenty trading-day period ending on September 29, 2021; and 3.0 million in unsecured promissory notes. 